36Kr learned that recently, the microfluidic and electrochemical testing platform enterprise Source Jingtaike officially completed the tens of millions of yuan preA round of financing exclusively invested by Yuansheng Venture Capital, which is the first time that the company has accepted external investment. This round of financing will be used for the upgrading of microfluidic PCR strip demonstration production line, the registration and reporting of microfluidic PCR equipment and reagents, the small-scale pilot of grass-roots nucleic acid detection, and the mass production of the first generation of electrochemical testing equipment and general detection reagents/consumables.
Microfluidic PCR strip detection system
Since its establishment more than three years ago, in addition to the research and development of traditional fluorescent PCR reagents, Yuanjing Taike has also invested its energy in the research and development of core components, key consumables and reagents related to molecular diagnosis, and has established two major technical platforms of microfluidic PCR strip and microfluidic electrochemistry for the development of efficient and low-cost molecular diagnostic products. Source Edgyoke's microfluidic PCR instrument and new coronavirus microfluidic PCR strip kit obtained CE certification in May 2021 and have been sold to many countries in Southeast Asia, the Middle East and Africa, and domestic reagent registration is also in progress. In addition, the company also completed the research and development of the first generation of electrochemical testing equipment and general detection reagents/consumables at the beginning of this year, and is currently in the first camp of the industrialization progress of China's electrochemical detection technology platform.
Electrochemical testing equipment
At the beginning of 2020, Zhu Kun, general manager of YuanjingTaike, led the R&D team to complete the research and development of sample collection, preservation, nucleic acid extraction, new coronavirus multiplefluorescence PCR detection, colloidal gold detection and all products in a very short period of time, and obtained a class I medical device filing, CE certification, FDA 510K exemption, and became the epidemic protection unit in Beijing, making important contributions to the prevention and control of the epidemic.
Source Regtech reagent product series
On this basis, the company's team also keenly found that air aerosol transmission is a weak link in the prevention and control of the new crown virus epidemic, and has successively launched a fully automatic air aerosol collector, microfluidic PCR detection system, atomization disinfection robot, plasma UV-C killing system, and has formed a closed loop of business for virus collection, on-site rapid detection, human-machine coexistence, real-time elimination, targeted killing, and killing effect evaluation in the air. It is reported that YuanjingTaike is currently the leading enterprise in China to form a closed-loop program, and this series of products has been used in hospitals, disease control, customs, animal breeding and other scenarios, and exported to more than ten countries such as Africa and Southeast Asia.
Integrated solution for air aerosol virus detection and removal
China's primary medical market is a huge blue ocean market for in vitro diagnosis in the future, and laboratory-free nucleic acid detection systems are also popular in many countries where PCR laboratories cannot be built on a large scale. The nucleic acid detection backpack laboratory independently developed by Regent Taike has the characteristics of convenience, speed, accuracy and inexpensiveness, and users can get accurate test results without professional training. In addition, the company also prepared a source view society app for customers very intimately, providing detailed product operation training videos for everyone to use worry-free. Based on the platform, Yuanjingtaike will develop a variety of pathogen nucleic acid detection products, such as new coronavirus, influenza virus, tuberculosis and other respiratory pathogens, rotavirus, Clostridium difficile pathogen detection, etc., to facilitate the first diagnosis in the community.
Nucleic acid testing backpack laboratory + Source View Society APP
For the success of this financing, Zhu Kun, chairman of YuanjingTaike, said: The future of inspection lies in the popularization of primary medical care in China and the testing of relatively backward countries, and the goal of Yuanjingtaike is to meet the growing demand for healthy life of the people through innovation. At the beginning of its establishment, Yuanjing Taike insisted on doing cost-effective, customer-oriented molecular POCT products, the core components used in the detection, key consumables and reagents were all independently developed, at first it was really difficult, there was not much to refer to, and now it seems that this idea is right, avoiding the homogenization of the product, and only the products suitable for the Chinese market price system have its vitality. Our products have just been launched, still in the registration and declaration stage has been highly praised by the National Academy of Administration, the National Health Commission Grassroots Department and industry experts, and has received great attention from grassroots doctors, so that we have the confidence to develop more products suitable for grassroots first diagnosis on this basis, and make our own contribution to the revitalization of rural medical care in China. At the same time, we hope to change the current uneven distribution of global medical resources through technological platform innovation and product innovation, so that those countries that are relatively backward can also enjoy high-quality testing services. Thank you for the recognition and support of the existing shareholders of Yuansheng Venture Capital and YuanjingTaike! We will continue to deepen the microfluidic and electrochemical technology platform to provide iterative solutions for the in vitro diagnostic industry.
Yuanjing Taike continued to carry out rural medical revitalization project activities
Dr. Lin Yi, managing partner of Yuansheng Venture Capital, said that Yuansheng Venture Capital focuses on equity investment in the field of biomedical health in China, and has laid out more than 40 enterprises in the field of diagnosis and precision medicine, and the management team of Yuanjingtaike with Zhu Kun as the core has been deeply cultivating in the field of molecular diagnosis for nearly 20 years, from the underlying technology to market demand, there are comprehensive and profound grasps and understandings, it is fortunate that Yuansheng Venture Capital has the opportunity to invest in supporting the Yuanjingtaike team this time, and looks forward to the more efficient and low-cost molecular diagnostic products of Yuanjingtaike to be popularized in a wider range. In particular, electrochemical molecular diagnostic products can bring revolutionary technological breakthroughs.